Reported about 1 month ago
Cathie Wood, CEO of Ark Invest, has invested in Recursion Pharmaceuticals, a biotech company aiming to transform drug development through AI. Despite the company's potential to drastically reduce development costs and time, it has lost 78% of its value since going public in 2021, highlighting its speculative nature. While it has made some progress, including partnerships with major pharmaceutical firms and successful initial clinical results, investors should be cautious and consider their risk tolerance before following Wood's lead.
Source: YAHOO